Electronic Submission Process for Requesting Export Certificates From the Center for Devices and Radiological Health; Availability, 4418-4419 [2013-01164]
Download as PDF
4418
Federal Register / Vol. 78, No. 14 / Tuesday, January 22, 2013 / Notices
under OMB control number 0910–0338.
The collections of information in 21
CFR part 814, subpart B for PMAs have
been approved under OMB control
number 0910–0231.
Dated: January 15, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
II. Background on the Electronic
Submission of Requests for Export
Certificates
[FR Doc. 2013–01069 Filed 1–18–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–1255]
Electronic Submission Process for
Requesting Export Certificates From
the Center for Devices and
Radiological Health; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of an electronic submission
process for requesting export certificates
for products regulated by FDA’s Center
for Devices and Radiological Health
(CDRH). The electronic process will
help fulfill both the legislative and
application time processing
requirements set out by the FDA Export
Reform and Enhancement Act of 1996
and the terms of clearance of the Office
of Management and Budget approval
(OMB control number 0910–0498) of the
Form FDA 3613 series. The new
eSubmitter process will complement the
current paper-based process.
FOR FURTHER INFORMATION CONTACT:
Leila Lawrence, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 2668, Silver Spring,
MD 20993–0002, 301–796–5786, email:
Leila.Lawrence@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
tkelley on DSK3SPTVN1PROD with
I. How eSubmitter Impacts FDA’s
Current Process
FDA currently accepts requests for
export certificates submitted by mail.
This process will remain in place and
would be augmented by the new
eSubmitter process.
For general user assistance, contact
the Center for Devices and Radiological
Health (CDRH), Division of Small
Manufacturers, International and
Consumer Assistance (DSMICA) by
telephone: 1–800–638–2041 or 301–
796–7100; or by email:
dsmica@fda.hhs.gov.
VerDate Mar<15>2010
18:11 Jan 18, 2013
Jkt 229001
You can find information about FDA’s
Electronic Submissions Gateway online
at: https://www.fda.gov/ForIndustry/
ElectronicSubmissionsGateway/
default.htm. Email questions about the
system to FDA’s Electronic Submissions
Gateway Help Desk: esgreg@gnsi.com.
FDA introduces an electronic option
for submitting requests for export
certificates of devices regulated by
CDRH as a voluntary alternative to
paper submissions. With electronic
submissions, CDRH can more readily
receive and process the export requests.
The electronic process will be
introduced in two phases. In the first
phase of operation, the CDRH Export
Certification Application and Tracking
System (CECATS) will be made
available to industry for the electronic
submission of requests for export
certificates.
CECATS is a Web-based application
used by FDA’s CDRH to process,
manage, and administer certificates for
the export of medical devices. CDRH
will be implementing the electronic
submission and review process.
Industry will have an option to submit
electronically or via the paper process.
CECATS will be accessible through the
FDA Unified Registration and Listing
System (FURLS). A firm must have a
FURLS account to access CECATS.
The CECATS module is a part of the
FURLS application within the FDA
Industry Systems Portal utilized to
automatically issue the certificate to
U.S. medical device manufacturers/
distributors who wish to export their
medical devices to foreign countries.
CECATS will help fulfill both the
legislative and application time
processing requirements set out by the
FDA Export Reform and Enhancement
Act of 1996 (Public Law 104–134) and
the terms of clearance of the OMB
approval of the Form FDA 3613 series.
CECATS will provide industry the
option of submitting export requests
electronically. Electronic submission
will automate many of the steps that
both industry and CDRH must perform
to submit and process export
certificates. The advantages to industry
will be:
• Certificate processing time will be
greatly reduced;
• Automated real-time validation will
eliminate the need to return
submissions; and
• Industry will receive real-time
updates on the status of their requests
via the Web.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
In early 2013, FDA will implement
phase two for the remainder of the
export certification, notification, and
permit requests listed as follows:
• Certificates of Exportability
(sections 801(e)(1) and 802 of the FD&C
Act);
• Non-Clinical Research Use Only
Certificate;
• Simple Notifications (section 802(g)
of the FD&C Act); and
• Export Permit Letter (section
801(e)(2) of the FD&C Act).
Upon full implementation in 2013,
industry will be able to submit all
export requests electronically. This is a
‘‘win’’ for both industry and CDRH as it
will allow us to process all export
requests more efficiently and
expeditiously. CDRH is developing
webinars and will hold online training
sessions with industry on how to access
and use CECATS. A schedule and
detailed instructions will be sent to
industry and posted to our Web site at:
https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
ImportingandExportingDevices/
ucm050521.htm#ref when they become
available.
Evaluation of the electronic
submission process will be conducted
periodically to further enhance both
user interface and data collection needs
as they become known to FDA.
Electronic submissions of requests for
export certificates will remain voluntary
at this time.
The printable forms can be viewed at
the following links:
• Form FDA 3613: Supplementary
Information Certificate for Foreign
Government Requests: https://
inside.fda.gov:9003/ucm/groups/
insidefda-public/@inside-adm-forms/
documents/form/ucm012794.pdf;
• Form FDA 3613a: Supplementary
Information Certificate of Exportability
Requests: https://inside.fda.gov:9003/
ucm/groups/insidefda-public/@insideadm-forms/documents/form/
ucm012795.pdf;
• Form FDA 3613c: Supplementary
Information Non-Clinical Research Use
Only Certificate: https://
inside.fda.gov:9003/ucm/groups/
insidefda-public/@inside-adm-forms/
documents/form/ucm012797.pdf.
III. What happens when the new
eSubmitter process for requesting
export certificates is implemented?
Implementation of the eSubmitter
process will supplement the ability to
request export certificates from CDRH
via paper. The new Web-based
application (available at: https://
www.access.fda.gov/oaa/index.jsp) uses
your existing FURLS account
E:\FR\FM\22JAN1.SGM
22JAN1
Federal Register / Vol. 78, No. 14 / Tuesday, January 22, 2013 / Notices
information. The Web site provides an
alternative to the paper request process
by enabling online submission of export
certificate applications.
IV. Paperwork Reduction Act of 1995
This document refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by OMB under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
CECATS and Forms FDA 3613, 3613a,
and 3613c have been approved under
OMB control number 0910–0498.
Dated: January 15, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–01164 Filed 1–18–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
tkelley on DSK3SPTVN1PROD with
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Cardiovascular Sciences.
Date: February 7–8, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Bradley Nuss, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC7814, Bethesda, MD 20892, 301–451–
8754, nussb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR–10–
244, Structure and Function of Opioid
Receptors.
Date: February 11–12, 2013.
Time: 8:00 a.m. to 12:00 p.m.
VerDate Mar<15>2010
18:11 Jan 18, 2013
Jkt 229001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: David R. Jollie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4150,
MSC 7806, Bethesda, MD 20892, (301) 435–
1722, jollieda@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Biomedical
Imaging and Engineering Area Review.
Date: February 12, 2013.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jan Li, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5106,
Bethesda, MD 20892, 301–435–1049, lij21@
csr.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group,
Hypertension and Microcirculation Study
Section.
Date: February 14, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Dallas Marriott Suites Medical—
Market Center, 2493 North Stemmons
Freeway, Dallas, TX 75207.
Contact Person: Ai-Ping Zou, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118,
MSC 7814, Bethesda, MD 20892, 301–408–
9497, zouai@csr.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group,
Bacterial Pathogenesis Study Section.
Date: February 19, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Richard G Kostriken,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7808, Bethesda, MD 20892, 301–402–
4454, kostrikr@csr.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group,
Molecular and Cellular Hematology Study
Section.
Date: February 19–20, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Luis Espinoza, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6183,
MSC 7804, Bethesda, MD 20892, 301–495–
1213, espinozala@mail.nih.gov.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
4419
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Integrative Neuroscience.
Date: February 19, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Nicholas Gaiano, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5178, MSC 7844, Bethesda, MD
20892–7844, 301–435–1033,
gaianonr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Nanotechnology and Molecular
Substrates in Brain and Retinal Disorders.
Date: February 19, 2013.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Yvonne Bennett, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5199, MSC 7846, Bethesda, MD
20892, 301–379–3793, bennetty@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 15, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–01096 Filed 1–18–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Draft Report on Carcinogens
Monographs for 1-Bromopropane and
Cumene; Availability of Documents;
Request for Comments; Notice of
Meeting
Peer review meeting of the
Draft Report on Carcinogens (RoC)
Monographs for 1-Bromopropane and
Cumene. These documents were
prepared by the Office of the Report on
Carcinogens (ORoC), Division of the
National Toxicology Program (DNTP),
National Institute of Environmental
Health Sciences (NIEHS).
DATES: Meeting: March 21, 2013, 1:00
p.m. to approximately 5:00 p.m. Eastern
Daylight Time (EDT) and March 22,
2013, from 8:30 a.m. until adjournment,
approximately 2:00 p.m. EDT.
Document Availability: Draft
monographs will be available by January
SUMMARY:
E:\FR\FM\22JAN1.SGM
22JAN1
Agencies
[Federal Register Volume 78, Number 14 (Tuesday, January 22, 2013)]
[Notices]
[Pages 4418-4419]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01164]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-1255]
Electronic Submission Process for Requesting Export Certificates
From the Center for Devices and Radiological Health; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of an electronic submission process for requesting export
certificates for products regulated by FDA's Center for Devices and
Radiological Health (CDRH). The electronic process will help fulfill
both the legislative and application time processing requirements set
out by the FDA Export Reform and Enhancement Act of 1996 and the terms
of clearance of the Office of Management and Budget approval (OMB
control number 0910-0498) of the Form FDA 3613 series. The new
eSubmitter process will complement the current paper-based process.
FOR FURTHER INFORMATION CONTACT: Leila Lawrence, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 2668, Silver Spring, MD 20993-0002, 301-796-5786,
email: Leila.Lawrence@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. How eSubmitter Impacts FDA's Current Process
FDA currently accepts requests for export certificates submitted by
mail. This process will remain in place and would be augmented by the
new eSubmitter process.
For general user assistance, contact the Center for Devices and
Radiological Health (CDRH), Division of Small Manufacturers,
International and Consumer Assistance (DSMICA) by telephone: 1-800-638-
2041 or 301-796-7100; or by email: dsmica@fda.hhs.gov.
You can find information about FDA's Electronic Submissions Gateway
online at: https://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/default.htm. Email questions about the system to FDA's Electronic
Submissions Gateway Help Desk: esgreg@gnsi.com.
II. Background on the Electronic Submission of Requests for Export
Certificates
FDA introduces an electronic option for submitting requests for
export certificates of devices regulated by CDRH as a voluntary
alternative to paper submissions. With electronic submissions, CDRH can
more readily receive and process the export requests.
The electronic process will be introduced in two phases. In the
first phase of operation, the CDRH Export Certification Application and
Tracking System (CECATS) will be made available to industry for the
electronic submission of requests for export certificates.
CECATS is a Web-based application used by FDA's CDRH to process,
manage, and administer certificates for the export of medical devices.
CDRH will be implementing the electronic submission and review process.
Industry will have an option to submit electronically or via the paper
process. CECATS will be accessible through the FDA Unified Registration
and Listing System (FURLS). A firm must have a FURLS account to access
CECATS.
The CECATS module is a part of the FURLS application within the FDA
Industry Systems Portal utilized to automatically issue the certificate
to U.S. medical device manufacturers/distributors who wish to export
their medical devices to foreign countries.
CECATS will help fulfill both the legislative and application time
processing requirements set out by the FDA Export Reform and
Enhancement Act of 1996 (Public Law 104-134) and the terms of clearance
of the OMB approval of the Form FDA 3613 series.
CECATS will provide industry the option of submitting export
requests electronically. Electronic submission will automate many of
the steps that both industry and CDRH must perform to submit and
process export certificates. The advantages to industry will be:
Certificate processing time will be greatly reduced;
Automated real-time validation will eliminate the need to
return submissions; and
Industry will receive real-time updates on the status of
their requests via the Web.
In early 2013, FDA will implement phase two for the remainder of
the export certification, notification, and permit requests listed as
follows:
Certificates of Exportability (sections 801(e)(1) and 802
of the FD&C Act);
Non-Clinical Research Use Only Certificate;
Simple Notifications (section 802(g) of the FD&C Act); and
Export Permit Letter (section 801(e)(2) of the FD&C Act).
Upon full implementation in 2013, industry will be able to submit
all export requests electronically. This is a ``win'' for both industry
and CDRH as it will allow us to process all export requests more
efficiently and expeditiously. CDRH is developing webinars and will
hold online training sessions with industry on how to access and use
CECATS. A schedule and detailed instructions will be sent to industry
and posted to our Web site at: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ImportingandExportingDevices/ucm050521.htm#ref when they become available.
Evaluation of the electronic submission process will be conducted
periodically to further enhance both user interface and data collection
needs as they become known to FDA. Electronic submissions of requests
for export certificates will remain voluntary at this time.
The printable forms can be viewed at the following links:
Form FDA 3613: Supplementary Information Certificate for
Foreign Government Requests: https://inside.fda.gov:9003/ucm/groups/insidefda-public/@inside-adm-forms/documents/form/ucm012794.pdf;
Form FDA 3613a: Supplementary Information Certificate of
Exportability Requests: https://inside.fda.gov:9003/ucm/groups/insidefda-public/@inside-adm-forms/documents/form/ucm012795.pdf;
Form FDA 3613c: Supplementary Information Non-Clinical
Research Use Only Certificate: https://inside.fda.gov:9003/ucm/groups/insidefda-public/@inside-adm-forms/documents/form/ucm012797.pdf.
III. What happens when the new eSubmitter process for requesting export
certificates is implemented?
Implementation of the eSubmitter process will supplement the
ability to request export certificates from CDRH via paper. The new
Web-based application (available at: https://www.access.fda.gov/oaa/index.jsp) uses your existing FURLS account
[[Page 4419]]
information. The Web site provides an alternative to the paper request
process by enabling online submission of export certificate
applications.
IV. Paperwork Reduction Act of 1995
This document refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by OMB under the Paperwork Reduction Act of 1995
(44 U.S.C. 3501-3520). The collections of information in CECATS and
Forms FDA 3613, 3613a, and 3613c have been approved under OMB control
number 0910-0498.
Dated: January 15, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-01164 Filed 1-18-13; 8:45 am]
BILLING CODE 4160-01-P